CHERAMIE RAMI: Open Payments
NPI 1720543168 · BREAUX BRIDGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$386 in 18 payments from 11 companies in 2025. Trend: 2023 $300 · 2024 $339 · 2025 $386
Food & beverage: $386
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| ABBVIE INC. | 2 | $46 |
| Phadia US Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| SCPHARMACEUTICALS INC. | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: FANAPT, Auvelity, CAPLYTA, VRAYLAR, ImmunoCAP, MOUNJARO, Dexcom G6 Transmitter, FUROSCIX.
Industry payments across LA — which companies pay providers there.
